Abstract 124P
Background
BRAF V600E is identified approximately 5-9% of colorectal cancer (CRC) patients. Non-V600E BRAF mutation is characterized a rare molecular subtype. The clinical characteristics and prognostic impact of non-V600 BRAF mutants are not well defined.
Methods
We recruited 829 patients with CRC from our institution. Tissue samples were molecularly tested. Clinical data was retrospectively reviewed and analyzed using Chi-square and t-test. Overall survival (OS) was compared by log-rank test.
Results
All BRAF mutation was detected in 50 (6%) patients including 24 (3%) patients with non-V600 mutations. Patient characteristics and BRAF testing technique were not significantly different based on BRAF status and it was comparable between BRAF V600E and non-V600 groups. There were significantly more ALL RAS and PIK3CA mutations in non-V600 mutant patients. Patients with non-V600 mutation had median OS of 82 months which was longer than BRAF WT, 66 months, and 31 months of BRAF V600E group, respectively (P=0.067). OS according to treatment with anti-EGFR in metastatic CRC patients was not significantly different in both V600E and non-V600 BRAF mutant groups. Table: 124P
BRAF-MT (n=50) | |||||||
BRAF-WT (n=779) | BRAF-MT (n=50) | p-value | V600 (n=26) | non-V600 (n=24) | p-value | ||
Age | 63 (18 - 93) | 65 (19-85) | 66 (19 - 85) | 65 (24 - 83) | |||
Sex | |||||||
Male | 471 (60) | 32 (64) | 0.62 | 15 (58) | 17 (71) | 0.333 | |
Female | 308 (40) | 18 (36) | 11 (42) | 7 (29) | |||
Sidedness | |||||||
Left | 591 (76) | 33 (66) | 0.289 | 12 (70) | 15 (62) | 0.878 | |
Right | 168 (22) | 15 (30) | 7 (27) | 8 (33) | |||
non-specify | 20 (3) | 2 (4) | 1 (4) | 1 (4) | |||
Technique | |||||||
NGS | 547 (70) | 38 (76) | 0.466 | 18 (69) | 20 (83) | 0.26 | |
Pyrosequencing | 84 (11) | 6 (12) | 5 (19) | 1 (4) | |||
PCR | 148 (19) | 6 (12) | 3 (12) | 2 (12) | |||
All RAS mutation | 418 (54) | 8 (16) | <0.001 | 0 | 8 (33) | 0.001 | |
PIK3CA mutation | 94 (12) | 9 (18) | 0.218 | 1 (4) | 8 (33) | 0.009 | |
Recur/Met | (n=575) | (n=35) | (n=19) | (n=16) | |||
Anti-VEGF | 105 (18) | 7 (20) | 0.796 | 2 (11) | 5 (31) | 0.207 | |
Anti-EGFR | 162 (28) | 6 (17) | 0.156 | 3 (16) | 3 (19) | 1 |
Conclusions
Non-V600 BRAF mutation may indicate better prognosis. The difference in treatment effect was not demonstrated in patients with BRAF mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of medicine Ramathibodi Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract